The Lawyer Asia Pacific 150 is the only research report to provide a ranking of the top 100 independent local firms and top 50 global firms in the region. The report offers critical review of some of the fastest growing firms and their strategies, a country-by-country guide to leading legal advisers and legal services market trends, plus exclusive insight into the current business development opportunities in the Asia Pacific. Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
Ashurst Morris Crisp has lost out to Allen & Overy (A&O) following a management reshuffle at British Biotech
A&O was brought on board by Peter Fellner, the company's new chairman, when former chief executive Elliot Goldstein was ousted late last year.
A&O has been brought in at a good time, because British Biotech has just sealed a £52m merger with rival RiboTargets. The firm acted on the merger and is now in a good position to gain further work as the biotech sector consolidates.
Slaughter and May has also worked for British Biotech in the past, but Ashursts was brought in on the company's last big deal, its unsuccessful bid for MorphoSys. The client partner at Ashursts is Michael Robbins.
However, when Fellner arrived in the latest of a series of key management changes at British Biotech, he brought his law firm with him. A&O has acted for Celltech, of which Fellner has been chief executive since 1993.